Tissue and Pathology The Tissue and Pathology Core Resource will provide tissue to SPORE investigators for transiatkmal research projects and limited pathology research services to SPORE projects. The Tissue and Pathology Core maintains several distributed tissue banks: At the MGH, blood from women with breast cancer or who have a high risk for breast cancer is stored. Also at the MGH, tissue from the operating room is stored. The BWH stores a variety of tissues from breast operations conducted in their operating rooms. The DFC1 holds blood from women seen in its Breast Oncology Clinic with breast cancer, and from women with an increased risk for breast cancer seen in risk evaluation programs. At the BIDMC, a large collection of archived, paraffin embedded blocks is kept linked to a database containing clinical information without patient identifiers but with detailed pathologic descriptions in searchable data fields. The BIDMC maintains a SPORE research pathology laboratory, which will perform immunohistochemistry, fluorescent in-situ hybridi/ation, and other simple or complex histologic applications. This service is available to SPORE projects, including Developmental Projects and Career Developmental Awardees. The tissues are available to SPORE investigators, DF/HCC members and other collaborating investigators on a case-by-case basis. The Tissue and Pathology Core participates in the Core Coordinating Committee and abides by its policies and procedures.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA089393-10
Application #
7927070
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
10
Fiscal Year
2009
Total Cost
$149,933
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Kabraji, Sheheryar; Ni, Jing; Lin, Nancy U et al. (2018) Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clin Cancer Res 24:1795-1804
Punglia, Rinaa S; Jiang, Wei; Lipsitz, Stuart R et al. (2018) Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. Breast Cancer Res Treat 167:751-759
Liu, Hui; Murphy, Charles J; Karreth, Florian A et al. (2018) Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. Cancer Discov 8:354-369
Asdourian, Maria S; Swaroop, Meyha N; Sayegh, Hoda E et al. (2017) Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral Surgery. J Clin Oncol 35:3934-3941
Kochupurakkal, Bose S; Iglehart, J Dirk (2016) Identification of genes responsible for RelA-dependent proliferation arrest in human mammary epithelial cells conditionally expressing RelA. Genom Data 7:92-3
Vaz-Luis, Ines; Hughes, Melissa E; Cronin, Angel et al. (2016) Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Res Treat 155:569-78
Sun, Fangdi; Skolny, Melissa N; Swaroop, Meyha N et al. (2016) The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema. Breast Cancer Res Treat 157:229-240
Ferguson, Chantal M; Swaroop, Meyha N; Horick, Nora et al. (2016) Impact of Ipsilateral Blood Draws, Injections, Blood Pressure Measurements, and Air Travel on the Risk of Lymphedema for Patients Treated for Breast Cancer. J Clin Oncol 34:691-8
Miller, Cynthia L; Colwell, Amy S; Horick, Nora et al. (2016) Immediate Implant Reconstruction Is Associated With a Reduced Risk of Lymphedema Compared to Mastectomy Alone: A Prospective Cohort Study. Ann Surg 263:399-405
Sherr, Charles J; Beach, David; Shapiro, Geoffrey I (2016) Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov 6:353-67

Showing the most recent 10 out of 291 publications